Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Immune-mediated inflammation across disease boundaries: breaking down research silos

If new treatments for immune-mediated inflammatory diseases (IMIDs) are to emerge, then a radical new approach that moves the field from one that is based on clinical signs and symptoms to one that is based on immunological and molecular mechanisms is urgently needed. This requires a new way of thinking: that IMIDs should be approached as having shared common pathogenic cells and pathways, and that therapies should be targeted at these cells and processes rather than clinical features.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Commonalities in autoimmune diseases.
Fig. 2: The need for a mechanistic marker to explore shared versus specific pathways in IMIDs.

References

  1. Robinson, D. Jr et al. Curr. Med. Res. Op. 22, 989–1000 (2006).

    Article  Google Scholar 

  2. Krishna, M. T. et al. Eur. Respir. J. 54, 1900476 (2019).

    Article  Google Scholar 

  3. Kuek, A., Hazleman, B. L. & Ostör, A. J. Postgrad. Med. J. 83, 251–260 (2007).

    Article  CAS  Google Scholar 

  4. Dinse, G. E. et al. Arthrit. Rheumatol. 72, 1026–1035 (2020).

    Article  CAS  Google Scholar 

  5. Tracey, D. et al. Pharmacol. Ther. 117, 244–279 (2008).

    Article  CAS  Google Scholar 

  6. Wijbrandts, C. A. & Tak, P. P. Mayo Clin. Proc. 92, 1129–1143 (2017).

    Article  CAS  Google Scholar 

  7. Corcoran, S. E., Halai, R. & Cooper, M. A. Pharmacol. Rev. 73, 968–1000 (2021).

    Article  CAS  Google Scholar 

  8. Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. Nat. Rev Immunol. 21, 548–569 (2021).

    Article  CAS  Google Scholar 

  9. Buckley, C. D. Nat. Rev. Immunol. 13, 59–66 (2013).

    Article  CAS  Google Scholar 

  10. Cárdenas-Roldán, J., Rojas-Villarraga, A. & Anaya, J.-M. BMC Med. 11, 73 (2013).

    Article  Google Scholar 

  11. Zenewicz, L. A., Abraham, C., Flavell, R. A. & Cho, J. H. Cell 140, 791–797 (2010).

    Article  CAS  Google Scholar 

  12. Okada, Y. et al. Nature 506, 376–381 (2014).

    Article  CAS  Google Scholar 

  13. David, T., Ling, S. F. & Barton, A. Clin. Exp. Immunol. 193, 3–12 (2018).

    Article  CAS  Google Scholar 

  14. Shooshtari, P., Huang, H. & Cotsapas, C. Am. J. Human. Gen. 101, 75–86 (2017).

    Article  CAS  Google Scholar 

  15. Shen, N. et al. Nat. Rev. Rheumatol. 8, 701–709 (2012).

    Article  CAS  Google Scholar 

  16. Worthington, J. & Silman, A. Clin. Exp. Immunol. 101, 390–392 (1995).

    Article  CAS  Google Scholar 

  17. Tough, D. F., Tak, P. P., Tarakhovsky, A. & Prinjha, R. K. Nat. Rev. Drug Discov. 15, 835–853 (2016).

    Article  CAS  Google Scholar 

  18. Sims, E. K. et al. Sci. Transl. Med. 13, eabc8980 (2021).

    Article  CAS  Google Scholar 

  19. Gerlag, D. M. et al. Ann. Rheum. Dis. 78, 179–185 (2019).

    Article  CAS  Google Scholar 

  20. Jumper, J. et al. Nature 596, 583–589 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yuti Chernajovsky.

Ethics declarations

Competing interests

C.D.B. is a founder of Mestag with founding equity (https://mestagtherapeutics.com). L.K.M. is an employee and has shares in GSK. All other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buckley, C.D., Chernajovsky, L., Chernajovsky, Y. et al. Immune-mediated inflammation across disease boundaries: breaking down research silos. Nat Immunol 22, 1344–1348 (2021). https://doi.org/10.1038/s41590-021-01044-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-021-01044-7

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing